This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carr, R.
Right arrow Articles by Lindo, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carr, R.
Right arrow Articles by Lindo, D.
Related Collections
Right arrow Premature & Newborn

PEDIATRICS Vol. 103 No. 4 April 1999, pp. 796-802

A Randomized, Controlled Trial of Prophylactic Granulocyte-Macrophage Colony-Stimulating Factor in Human Newborns Less Than 32 Weeks Gestation

Received Sep 14, 1998; accepted Jan 4, 1999.

Robert Carr*, Neena Modi§, Caroline J. Doréparallel , Rim El-RifaiDagger , and Dwight Lindo§

From the * Departments of Haematology and Dagger  Paediatrics, King's College, St Thomas' Hospital; the § Department of Paediatrics and Neonatal Medicine; and the parallel  Department of Medical Statistics and Evaluation, Imperial College School of Medicine, Hammersmith Hospital, London, United Kingdom.

Objective.  Preterm neonates undergoing intensive care have high morbidity from sepsis. These infants also frequently develop neutropenia, and when this is associated with sepsis, mortality is high. This study investigates the potential for granulocyte-macrophage colony-stimulating factor (GM-CSF) to effect a clinically relevant increase in neutrophil number when used prophylactically in high-risk preterm neonates, and assesses its safety in this population.

Design.  In an open, randomized, controlled study, 75 neonates (25 small for gestational age) <32 weeks gestation were randomized to receive GM-CSF (10 µg/kg/d) by subcutaneous injection for 5 days from <72 hours after birth, or to a control group. The primary outcome measure was the neutrophil count during 14 days from study entry. The infants were monitored for potential toxicity. Clinical outcomes, sepsis, and mortality, were recorded, but this initial study was not designed to address clinical benefit.

Results.  Prophylactic GM-CSF therapy completely abolished neutropenia in treated infants, when both well and septic, throughout the period of study. Neutropenia (<= 1.7 × 109/L) developed in 16 of 39 control infants. Five control infants experienced an acute decrease in neutrophil count coincident with the onset of sepsis. There was no evidence of hematologic, respiratory, or gastrointestinal toxicity in treated infants. Treated infants had a trend to fewer symptomatic, blood culture positive septic episodes than controls during 2 weeks from study entry (11/36 vs 18/39).

Conclusion.  Five-day prophylactic GM-CSF completely abolishes postnatal neutropenia and sepsis-induced neutropenia in preterm neonates at high risk of sepsis, and so removes an important risk factor for sepsis and sepsis-related mortality.GM-CSF, preterm neonates, neutropenia, sepsis. .




This article has been cited by other articles:


Home page
 NeoReviewsHome page
T. D. Soltau and R. L. Schelonka
Immune Modification to Prevent Nosocomial Sepsis in Hospitalized Newborns
NeoReviews, May 1, 2008; 9(5): e199 - e205.
[Abstract] [Full Text] [PDF]

Home page
 NeoReviewsHome page
A. Maheshwari and R. D. Christensen
Neutropenia in the Neonatal Intensive Care Unit
NeoReviews, October 1, 2004; 5(10): e431 - e443.
[Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
D. Kaufman and K. D. Fairchild
Clinical Microbiology of Bacterial and Fungal Sepsis in Very-Low-Birth-Weight Infants
Clin. Microbiol. Rev., July 1, 2004; 17(3): 638 - 680.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
N A Murray and I A G Roberts
Neonatal transfusion practice
Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2004; 89(2): F101 - F107.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
I Roberts and N A Murray
Neonatal thrombocytopenia: causes and management
Arch. Dis. Child. Fetal Neonatal Ed., September 1, 2003; 88(5): F359 - F364.
[Abstract] [Full Text] [PDF]

Home page
 NeoReviewsHome page
R. A. Polin and L. Saiman
Nosocomial Infections in the Neonatal Intensive Care Unit
NeoReviews, March 1, 2003; 4(3): e81 - 89.
[Full Text] [PDF]

Home page
 PediatricsHome page
E. Miura, R. S. Procianoy, C. Bittar, C. S. Miura, M. S. Miura, C. Mello, and R. D. Christensen
A Randomized, Double-Masked, Placebo-Controlled Trial of Recombinant Granulocyte Colony-Stimulating Factor Administration to Preterm Infants With the Clinical Diagnosis of Early-Onset Sepsis
Pediatrics, January 1, 2001; 107(1): 30 - 35.
[Abstract] [Full Text]

Home page
 PediatricsHome page
K. Haspolat, S. Günbey, and O. Derman
A Randomized Trial of Granulocyte-Macrophage Colony-Stimulating Factor in Neonates With Sepsis and Neutropenia
Pediatrics, January 1, 2001; 107(1): 36 - 41.
[Abstract] [Full Text]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
N. Modi and R. Carr
Promising stratagems for reducing the burden of neonatal sepsis
Arch. Dis. Child. Fetal Neonatal Ed., September 1, 2000; 83(2): 150F - 153.
[Full Text]

Home page
 PediatricsHome page
D. K. N. Haque;, R. Carr, and N. Modi
Intravenous Immunoglobulins Versus Sepsis
Pediatrics, May 1, 2000; 105(5): 1173 - 1174.
[Full Text]